Omega Therapeutics CFO Joshua Reed to depart

On April 10, 2024, Omega Therapeutics and Joshua Reed, the company’s CFO, agreed to terminate his employment effective as of May 31, 2024. In connection with the termination, Mr. Reed will be entitled to receive the severance payments and benefits set forth in his employment agreement with the Company and extended exercisability of his exercisable Company stock options until the first anniversary of the Effective Date, in each case, subject to his entering into a separation agreement containing a release of claims. On April 16, 2024, the Board of Directors of the Company designated Barbara Chan, the Company’s Senior Vice President, Finance, as its principal financial officer and principal accounting officer, in each case effective on the Effective Date.